ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 709,75
0,98%
Dow Jones
43 487,83
0,78%
DAX
20 903,39
1,31%
Brent Oil
80,005
0,00%
Bitcoin
103 088,94
-1,00%
Registration Strip Icon for monitor Surveillez plusieurs cotations en temps réel des principales bourses, telles que Euronext Paris, NASDAQ, NYSE, AMEX, Bovespa et plus encore.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Xencor Inc (XNCR)

  7. Xencor Inc (XNCR) Actualités

XNCR

Xencor (XNCR)

Xencor Inc
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:XNCR
DateHeureSourceTitreSymboleSociété
13/01/202514h08Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:XNCRXencor Inc
26/11/202422h01Business WireXencor to Participate at Upcoming Investor ConferencesNASDAQ:XNCRXencor Inc
21/11/202422h21Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:XNCRXencor Inc
15/11/202400h38Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:XNCRXencor Inc
15/11/202400h16Edgar (US Regulatory)Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]NASDAQ:XNCRXencor Inc
06/11/202422h09Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:XNCRXencor Inc
06/11/202422h01Business WireXencor Reports Third Quarter 2024 Financial ResultsNASDAQ:XNCRXencor Inc
04/11/202413h00Business WireXencor Doses First Subject in Phase 1/2 Study of XmAb®942 in Development for Patients with Inflammatory Bowel DiseaseNASDAQ:XNCRXencor Inc
21/10/202422h18Edgar (US Regulatory)Form SC 13G - Statement of Beneficial Ownership by Certain InvestorsNASDAQ:XNCRXencor Inc
10/10/202414h09Business WireXencor Presents Preclinical Data on XmAb942, a High-Potency Extended Half-Life Anti-TL1A Antibody, to be Developed for Patients with Inflammatory Bowel DiseasesNASDAQ:XNCRXencor Inc
04/10/202414h01Business WireXencor Announces Upcoming Change to Board of DirectorsNASDAQ:XNCRXencor Inc
12/09/202422h01Business WireXencor Announces Closing of Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional SharesNASDAQ:XNCRXencor Inc
12/09/202414h45Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:XNCRXencor Inc
11/09/202412h31Business WireXencor Announces Pricing of $175 Million Public Offering of Common StockNASDAQ:XNCRXencor Inc
10/09/202422h01Business WireXencor Announces Proposed Public Offering of Common StockNASDAQ:XNCRXencor Inc
09/09/202413h31Business WireXencor Announces XmAb Drug Candidates in Autoimmune Disease with Near-Term Clinical Plans and Shares Clinical Progress in Early-Stage Oncology ProgramsNASDAQ:XNCRXencor Inc
06/09/202414h01Business WireXencor to Host Research & Development Webcast and Conference Call on Monday, September 9, 2024NASDAQ:XNCRXencor Inc
05/08/202422h01Business WireXencor Reports Second Quarter 2024 Financial ResultsNASDAQ:XNCRXencor Inc
13/06/202414h01Business WireXencor Regains CD20 x CD3 Bispecific T-Cell EngagerNASDAQ:XNCRXencor Inc
09/05/202422h09Business WireXencor Reports First Quarter 2024 Financial ResultsNASDAQ:XNCRXencor Inc
09/04/202414h01Business WireXencor Appoints Bart Cornelissen as Chief Financial OfficerNASDAQ:XNCRXencor Inc
28/02/202422h01Business WireXencor to Present at Upcoming Investor ConferencesNASDAQ:XNCRXencor Inc
27/02/202422h01Business WireXencor Reports Fourth Quarter and Full Year 2023 Financial ResultsNASDAQ:XNCRXencor Inc
20/02/202422h31Business WireXencor to Host Webcast to Review Fourth Quarter and Full Year 2023 Financial Results and Provide Vudalimab Clinical UpdateNASDAQ:XNCRXencor Inc
16/02/202423h43Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:XNCRXencor Inc
03/01/202422h01Business WireXencor to Present at the 42nd Annual J.P. Morgan Healthcare ConferenceNASDAQ:XNCRXencor Inc
02/01/202414h01Business WireDane Leone Joins Xencor as Senior Vice President, Corporate StrategyNASDAQ:XNCRXencor Inc
21/11/202322h01Business WireXencor to Present at the Piper Sandler 35th Annual Healthcare ConferenceNASDAQ:XNCRXencor Inc
07/11/202322h01Business WireXencor Sells Portion of Royalties and Milestones from Ultomiris® and Monjuvi® to OMERS Life Sciences for $215 MillionNASDAQ:XNCRXencor Inc
07/11/202322h01Business WireXencor Reports Third Quarter 2023 Financial ResultsNASDAQ:XNCRXencor Inc
 Showing the most relevant articles for your search:NASDAQ:XNCR

Dernières Valeurs Consultées

NYSE
JPM
JP Morgan Chase
EU
PX4
SBF 120
NASDAQ
MSFT
Microsoft
EU
AF
Air FranceKLM
FTSE
UKX
FTSE 100
EU
SGO
Cie de SaintGobain
NYSE
KO
Coca Cola
COIN
DOGEUSD
Dogecoin
EU
VK
Vallourec
SPI
SP500
S&P 500
EU
ACA
Credit Agricole
EU
LR
Legrand
EU
RI
Pernod Ricard
COIN
SOLUSD
Solana
EU
EN
Bouygues
NASDAQ
AAPL
Apple
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2025 ADVFN PLC - Tous droits réservés